Quality of Life in Adults With Untreated Fabry Disease in Sweden (QoLUF)
- Sponsor
- Vastra Gotaland Region
- Study ID
- NCT07560956
- Status
- Not Yet Recruiting
Notify me when recruiting opens
Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.
Add your contact details and location so we can keep your interest tied to this study.
Conditions
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Qualitative Interview — OTHERNon-interventional
Study Details
Fabry disease is a rare, inherited condition that can affect multiple organs, including the heart, kidneys, and nervous system. Many people with Fabry disease live for a period of time without receiving disease-specific treatment, for example because treatment criteria have not yet been met. There is limited knowledge about how patients experience this period without treatment. The purpose of this study is to improve understanding of how adults with Fabry disease who are not yet receiving disease-specific treatment experience their quality of life, their daily lives, and their contacts with health care services. This is a national interview study in which participants will take part in one individual digital interview lasting approximately 45-60 minutes. During the interview, participants will be invited to describe their experiences in their own words, including symptoms, how the disease affects everyday life, psychological and emotional well-being, and experiences of follow-up and support from health care providers. Participants will also complete a short questionnaire with basic background information, such as age, education, and living situation. By collecting and analyzing patients' own narratives, the study aims to identify needs, challenges, and support resources during the period without treatment. The results are expected to contribute to increased knowledge and to the development of more person-centered care for individuals living with Fabry disease.
Key Dates
- Start date
- May 1, 2026
- Status verified
- Apr 2026
- Primary completion
- Dec 31, 2027
- Completion
- Dec 31, 2027
Study Design
- Enrollment
- 35 participants (estimated)
Arms
- Arm: Adults with Fabry Disease Not Receiving Disease-Specific TreatmentThis group includes adult patients diagnosed with Fabry disease who are not currently receiving disease-specific treatment (such as enzyme replacement therapy or chaperone therapy). Participants are followed at national highly specialized care centers in Sweden and take part in a single qualitative interview to describe their experiences of living with Fabry disease without current treatment.
Primary Outcome Measure
Patient-reported experiences of quality of life while living with untreated Fabry disease [ Time Frame: Single assessment during one qualitative interview (approximately 45-60 minutes) ]
Central Contacts
- Dimitrios Chantzichristos, MD PhD+46 31 342 1000
Related Studies
- Fabry Disease Registry & Pregnancy Sub-registryRecruiting · Genzyme, a Sanofi Company · Birmingham, Alabama
- Natural History and Structural Functional Relationships in Fabry Renal Disease Treatment Outcomes(Changes)in Fabry Renal Disease StudyRecruiting · University of Minnesota · Minneapolis, Minnesota
- A Global Prospective Observational Study of Women With Fabry Disease and Their Infants During Pregnancy and BreastfeedingRecruiting · Amicus Therapeutics · Philadelphia, Pennsylvania
- Long-Term Follow-up of Subjects Who Were Treated With ST-920Enrolling By Invitation · Sangamo Therapeutics · Irvine, California